Human Growth Hormone / Somatropin

ID: human_growth_hormone

Aliases: hGH, GH, somatropin, recombinant human growth hormone, rhGH, SOMATROPIN (HGH)

Type: compound

Route/form: subcutaneous injection in approved somatropin products

Status: approved

Evidence level: approved / labelled

Best data tier: approved label + human controlled/review

Support scope: human, review/regulatory

Source types: government_review, human_rct, label, meta_analysis, review

Linked sources: 5

Broad outcomes: Fat loss / metabolic health, Hormones / fertility / sexual health, Longevity / mitochondrial / redox, Muscle growth / performance / recovery, PEDs / AAS / thermogenics

Reading note: These are curation notes anchored to linked sources, not a clinical recommendation or protocol.

Targets / mechanism

• growth hormone receptor agonist
• IGF-1 axis upregulation
• lipolysis and fluid-retention effects

Optimization domains

• growth hormone
• body composition
• muscle
• fat loss
• endocrine
• anti aging
• metabolic

Research basis

• Approved somatropin products provide a real subcutaneous GH-replacement and wasting/lipodystrophy evidence anchor with label-level monitoring and safety context.
• Human disease-context studies support lean-mass and body-composition effects, and healthy-adult meta-analyses make clear that GH can alter body composition even when athletic-performance transfer is weak or inconsistent.
• It anchors the GH/IGF side of the repository so tesamorelin, secretagogues, MK-677, mecasermin, and IGF analogs are not evaluated in isolation.

Limits, risks, and missing evidence

• GH-driven lean-mass increases can reflect water, connective tissue, and organ/tissue effects rather than proportional contractile strength or better sport performance.
• Edema, carpal-tunnel symptoms, arthralgia, insulin resistance/glucose issues, intracranial hypertension, neoplasm warnings, and acromegaly-like risk make casual anti-aging or physique claims misleading.
• Benefits in GH deficiency, HIV wasting/lipodystrophy, burns, or other disease states do not automatically generalize to healthy enhancement.

Risk flags

• prescription only
• glucose insulin risk
• fluid retention
• neoplasm warning
• medical supervision

Linked papers, labels, and reviews

1. DailyMed label: Nutropin AQ NuSpin somatropin injection
   label / dailymed_somatropin_label
   Official somatropin label; anchors approved GH-deficiency and related indications, subcutaneous route, and safety warnings.
2. A randomized, double-blind, placebo-controlled trial of human growth hormone for the treatment of wasting in AIDS
   human_rct / pubmed_somatropin_hiv_wasting_1996
   Direct recombinant human GH trial in AIDS wasting; supports lean-mass/wasting context, not healthy hypertrophy use.
3. Growth Hormone, IGF-1, and Insulin for Performance Enhancement
   government_review / ncbi_hgh_athletic_performance_review
   NCBI review of GH/IGF-1/insulin performance-enhancement claims and evidence limits.
4. Impact of GH administration on athletic performance in healthy young adults: A systematic review and meta-analysis of placebo-controlled trials
   meta_analysis / pubmed_hgh_athletic_performance_meta_2017
   Healthy-adult placebo-controlled GH evidence synthesis; useful for separating lean-mass/body-composition effects from actual athletic-performance outcomes.
5. Growth hormone administration: is it safe and effective for athletic performance
   review / pubmed_hgh_athletic_performance_review_2010
   Sports-endocrinology review of GH performance claims, adverse effects, and evidence limits in healthy users.